Orthocell Limited

ASX:OCC ISIN:AU000000OCC6

Orthocell Limited ASX:OCCOrthocell Limited (ASX:OCC) is a commercial-stage, regenerative medicine company focused on developing products for a variety of tendon, cartilage and soft tissue injuries. Orthocell's portfolio of products include TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI*TM) and Autologous Chondrocyte Implantation (Ortho-ACI*TM), which aim to regenerate damaged tendon and cartilage tissue. The Company's other major product is Celgro*TM, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals.

 
 
 

View in Other Languages

News

Chapmans Limited (ASX:CHP) to Make Strategic Medicinal Cannabis Sector Investment

🕔8/29/2017 12:35:47 PM 8668

The Directors of Chapmans Limited (ASX:CHP) are pleased to announce that the Company has entered into a Binding Heads of Agreement with MJ Life Sciences Pty Ltd, to make a strategic investment of US$500,000 in MJLS.

Read Full Article

Orthocell Limited (ASX:OCC) First Human Tendons Grown In Laboratory

🕔11/6/2014 11:41:32 AM 7283

Regenerative medicine company Orthocell Limited (ASX:OCC) announced today its success in growing human tendons in a laboratory for the first time.

Read Full Article
###

8,872 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 9) (Last 30 Days: 47) (Since Published: 4844) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.orthocell.com

More News Results

  • 2024/03/25: Part 1 Remplir US Market Authorisation Successfully Complete*
  • 2024/03/11: Cleansing Notice*
  • 2024/03/11: Application for quotation of securities - OCC*
  • 2024/03/11: Application for quotation of securities - OCC*
  • 2024/02/28: Cleansing Notice*
  • 2024/02/23: Appendix 4D & Half-Year Financial Statements*
  • 2024/02/22: Proposed issue of securities - OCC*
  • 2024/02/22: Strategic Placement to Raise $3.5 million*
  • 2024/02/20: Trading Halt*
*refer to company website